HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Cosmetics Directive

This article was originally published in The Rose Sheet

Executive Summary

European Commission proposes to recast the Cosmetics Directive from 1976 - now "a 'patchwork' of 55 amendments without coherent terminology" that is "ripe" for simplification, according to VP Günter Verheugen. A single regulation will take the place of 27 transposing national pieces of legislation representing over 3,500 pages of legal text, according to the EC, which launched a consultation soliciting stakeholder input on the process in January 2007 (1"The Rose Sheet" Jan. 22, 2007, p. 5). Proposal introduces clear minimum requirements for assessing product safety, among other measures intended to increase manufacturer responsibility for goods placed on the market. Draft also outlines rules for reporting adverse events related to product use, executing product withdrawal and coordinating enforcement programs. At the same time, simplified notification requirements for new cosmetics are expected to cut administration costs by 50%. In a Feb. 5 release, European Cosmetic Toiletry and Perfumery Association (Colipa) greets the simplification with open arms...

You may also be interested in...



European Parliament Adds Nanotech Regs To Updated Cosmetics Directive

Regulations on the use of nanotechnology in cosmetics have been added as the European Parliament recasts the Cosmetics Directive

European Cosmetics Regulation To Be Modernized By 2010; Comments Invited

Proposed simplification of the European Cosmetics Directive could strengthen the oversight of active ingredients while shifting regulatory focus to marketed products, rather than individual substances, and reducing administrative costs faced by industry

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel